Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two f...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 65; no. 4; pp. 1145 - 1155
Main Authors Petta, Salvatore, Wong, Vincent Wai‐Sun, Cammà, Calogero, Hiriart, Jean‐Baptiste, Wong, Grace Lai‐Hung, Marra, Fabio, Vergniol, Julien, Chan, Anthony Wing‐Hung, Di Marco, Vito, Merrouche, Wassil, Chan, Henry Lik‐Yuen, Barbara, Marco, Le‐Bail, Brigitte, Arena, Umberto, Craxì, Antonio, de Ledinghen, Victor
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.04.2017
Subjects
Online AccessGet full text
ISSN0270-9139
1527-3350
1527-3350
DOI10.1002/hep.28843

Cover

Abstract Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145‐1155).
AbstractList Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values.Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values.In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155).CONCLUSIONSIn patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155).
Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145‐1155).
Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132-298, middle 299-338, higher 339-400 dB/m). Among patients with F0-F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3-F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848-0.982; 0.830, 0.753-0.908; 0.806, 0.723-0.890). As a consequence, in subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (Hepatology 2017;65:1145-1155).
Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values. Patients (n = 324) were assessed by clinical and histological (Kleiner score) features. LSM and CAP were performed using the M probe. CAP values were grouped by tertiles (lower 132‐298, middle 299‐338, higher 339‐400 dB/m). Among patients with F0‐F2 fibrosis, mean LSM values, expressed in kilopascals, increased according to CAP tertiles (6.8 versus 8.6 versus 9.4, P = 0.001), and along this line the area under the curve of LSM for the diagnosis of F3‐F4 fibrosis was progressively reduced from lower to middle and further to higher CAP tertiles (0.915, 0.848‐0.982; 0.830, 0.753‐0.908; 0.806, 0.723‐0.890). As a consequence, in subjects with F0‐F2 fibrosis, the rates of false‐positive LSM results for F3‐F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher). Consistent with this, a decisional flowchart for predicting fibrosis was suggested by combining both LSM and CAP values. Conclusions: In patients with NAFLD, CAP values should always be taken into account in order to avoid overestimations of liver fibrosis assessed by transient elastography. (H epatology 2017;65:1145‐1155).
Author de Ledinghen, Victor
Merrouche, Wassil
Wong, Vincent Wai‐Sun
Cammà, Calogero
Chan, Henry Lik‐Yuen
Marra, Fabio
Barbara, Marco
Petta, Salvatore
Vergniol, Julien
Di Marco, Vito
Chan, Anthony Wing‐Hung
Wong, Grace Lai‐Hung
Arena, Umberto
Hiriart, Jean‐Baptiste
Craxì, Antonio
Le‐Bail, Brigitte
Author_xml – sequence: 1
  givenname: Salvatore
  surname: Petta
  fullname: Petta, Salvatore
  email: petsa@inwind.it, salvatore.petta@unipa.it
  organization: University of Palermo
– sequence: 2
  givenname: Vincent Wai‐Sun
  surname: Wong
  fullname: Wong, Vincent Wai‐Sun
  organization: The Chinese University of Hong Kong
– sequence: 3
  givenname: Calogero
  surname: Cammà
  fullname: Cammà, Calogero
  organization: University of Palermo
– sequence: 4
  givenname: Jean‐Baptiste
  surname: Hiriart
  fullname: Hiriart, Jean‐Baptiste
  organization: Bordeaux University Hospital
– sequence: 5
  givenname: Grace Lai‐Hung
  surname: Wong
  fullname: Wong, Grace Lai‐Hung
  organization: The Chinese University of Hong Kong
– sequence: 6
  givenname: Fabio
  surname: Marra
  fullname: Marra, Fabio
  organization: Università degli Studi di Firenze
– sequence: 7
  givenname: Julien
  surname: Vergniol
  fullname: Vergniol, Julien
  organization: Bordeaux University Hospital
– sequence: 8
  givenname: Anthony Wing‐Hung
  surname: Chan
  fullname: Chan, Anthony Wing‐Hung
  organization: The Chinese University of Hong Kong
– sequence: 9
  givenname: Vito
  surname: Di Marco
  fullname: Di Marco, Vito
  organization: University of Palermo
– sequence: 10
  givenname: Wassil
  surname: Merrouche
  fullname: Merrouche, Wassil
  organization: Bordeaux University Hospital
– sequence: 11
  givenname: Henry Lik‐Yuen
  surname: Chan
  fullname: Chan, Henry Lik‐Yuen
  organization: The Chinese University of Hong Kong
– sequence: 12
  givenname: Marco
  surname: Barbara
  fullname: Barbara, Marco
  organization: University of Palermo
– sequence: 13
  givenname: Brigitte
  surname: Le‐Bail
  fullname: Le‐Bail, Brigitte
  organization: Bordeaux University Hospital
– sequence: 14
  givenname: Umberto
  surname: Arena
  fullname: Arena, Umberto
  organization: Università degli Studi di Firenze
– sequence: 15
  givenname: Antonio
  surname: Craxì
  fullname: Craxì, Antonio
  organization: University of Palermo
– sequence: 16
  givenname: Victor
  surname: de Ledinghen
  fullname: de Ledinghen, Victor
  organization: Bordeaux University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27639088$$D View this record in MEDLINE/PubMed
BookMark eNqNksFu1DAQhi1URLcLB14AWeICh7R2nMT2EVWFVqoEBzhHjjNmXTl2sJ2t9tH6dri7Ww6VQJw8Gn3_718zc4ZOfPCA0FtKzikh9cUG5vNaiIa9QCva1rxirCUnaEVqTipJmTxFZyndEUJkU4tX6LTmHZNEiBV6uJnmGLYw4uJp_VYluwU8RxitzjZ4HAx2pRWxsUMMySY87I6dlK0xHlLCE6i0RJjAZ2w9nlW2pUz43ubNo7FyOmyCsxoblfOTfrSp6AArrcPis_U_sQkR6-BzDM6VTAUGv6h9kFlFNUEuuq1yC6TX6KVRLsGb47tGPz5ffb-8rm6_frm5_HRbaSY6VmnFKR215pJx1pmmMURCbfjAu0Z1ULfjMEihxoFpPnbNSDgMTVPTdmQA0mi2Rh8OvmVOv8q_uZ9s0uCc8hCW1FMhhGw7WvP_QFvJGesaUtD3z9C7sMQyqL0hoZy3JfEavTtSyzDB2M_RTiru-qf9FeDjAdBlNymC-YNQ0j_eRl9uo9_fRmEvnrHa5v1sc1TW_Utxbx3s_m7dX199Oyh-A95A0CA
CODEN HPTLD9
CitedBy_id crossref_primary_10_1097_MCG_0000000000001380
crossref_primary_10_3748_wjg_v30_i4_290
crossref_primary_10_1007_s10620_017_4592_0
crossref_primary_10_1016_j_cgh_2020_04_018
crossref_primary_10_1002_oby_24033
crossref_primary_10_1007_s00535_020_01686_8
crossref_primary_10_18632_aging_103522
crossref_primary_10_3390_nu11123070
crossref_primary_10_1016_j_clnu_2023_03_021
crossref_primary_10_1053_j_gastro_2018_12_036
crossref_primary_10_1111_apt_18215
crossref_primary_10_1111_apt_18176
crossref_primary_10_1016_j_cgh_2024_10_014
crossref_primary_10_1007_s00535_022_01932_1
crossref_primary_10_1016_j_jhep_2017_11_028
crossref_primary_10_1177_2050640619854671
crossref_primary_10_1186_s13244_024_01857_8
crossref_primary_10_1002_ueg2_12280
crossref_primary_10_1371_journal_pone_0182202
crossref_primary_10_1016_j_dld_2021_06_015
crossref_primary_10_1155_2021_8859338
crossref_primary_10_1016_j_ultrasmedbio_2024_01_002
crossref_primary_10_1371_journal_pgph_0003572
crossref_primary_10_1136_bmjgast_2017_000158
crossref_primary_10_1186_s12876_021_01974_4
crossref_primary_10_3389_fmed_2022_862879
crossref_primary_10_3390_biomedicines11082108
crossref_primary_10_1016_j_actbio_2021_01_019
crossref_primary_10_1111_apt_14529
crossref_primary_10_5005_jp_journals_10018_1425
crossref_primary_10_1111_apt_15298
crossref_primary_10_1016_j_ultrasmedbio_2020_11_015
crossref_primary_10_1097_MD_0000000000010462
crossref_primary_10_2147_HMER_S265473
crossref_primary_10_1007_s10620_020_06748_8
crossref_primary_10_1097_RLI_0000000000000529
crossref_primary_10_1155_2020_4217512
crossref_primary_10_3389_fphys_2022_1046497
crossref_primary_10_7759_cureus_65089
crossref_primary_10_14309_ajg_0000000000000153
crossref_primary_10_1186_s43066_020_00044_w
crossref_primary_10_1371_journal_pone_0221548
crossref_primary_10_1002_mp_15484
crossref_primary_10_1016_j_clinre_2021_101769
crossref_primary_10_3748_wjg_v24_i11_1250
crossref_primary_10_1111_liv_14001
crossref_primary_10_33590_emj_10310531
crossref_primary_10_1177_2050640619865133
crossref_primary_10_1038_nrgastro_2018_10
crossref_primary_10_1097_QAI_0000000000001936
crossref_primary_10_3748_wjg_v27_i1_80
crossref_primary_10_1111_ijcp_13635
crossref_primary_10_31083_j_rcm2203082
crossref_primary_10_1177_2050640619900820
crossref_primary_10_3350_cmh_2024_0506
crossref_primary_10_1155_grp_6722810
crossref_primary_10_1111_jgh_14963
crossref_primary_10_1186_s13063_020_4068_y
crossref_primary_10_1016_j_ultrasmedbio_2018_07_008
crossref_primary_10_1016_j_numecd_2021_04_028
crossref_primary_10_1016_j_ultrasmedbio_2024_03_013
crossref_primary_10_1016_j_clinre_2022_101957
crossref_primary_10_1016_j_ultrasmedbio_2024_03_014
crossref_primary_10_1097_MEG_0000000000001736
crossref_primary_10_1016_j_clinre_2019_03_009
crossref_primary_10_4166_kjg_2024_103
crossref_primary_10_1016_j_clnu_2022_07_003
crossref_primary_10_1016_j_eclinm_2022_101547
crossref_primary_10_1111_liv_13602
crossref_primary_10_3389_fendo_2023_1144838
crossref_primary_10_14218_JCTH_2017_00009
crossref_primary_10_4093_dmj_2020_0137
crossref_primary_10_1080_00952990_2020_1833211
crossref_primary_10_1016_j_clinre_2018_10_017
crossref_primary_10_1111_jgh_14311
crossref_primary_10_1111_apt_18061
crossref_primary_10_2214_AJR_22_27656
crossref_primary_10_3390_metabo14010052
crossref_primary_10_3390_diagnostics13071236
crossref_primary_10_1007_s11695_020_04513_4
crossref_primary_10_1136_postgradmedj_2018_136111
crossref_primary_10_3390_biomedicines8090298
crossref_primary_10_1177_2050640618792819
crossref_primary_10_1016_S2468_1253_18_30077_3
crossref_primary_10_1007_s11695_020_05002_4
crossref_primary_10_1016_j_medcli_2019_01_030
crossref_primary_10_1097_HEP_0000000000000852
crossref_primary_10_3389_fimmu_2020_634409
crossref_primary_10_1007_s10278_021_00521_7
crossref_primary_10_2174_1381612826666200521133307
crossref_primary_10_1007_s10396_021_01106_1
crossref_primary_10_1016_j_medcle_2019_06_010
crossref_primary_10_1007_s12072_022_10368_x
crossref_primary_10_1097_MEG_0000000000000919
crossref_primary_10_1002_hep4_1719
crossref_primary_10_1111_apt_14219
crossref_primary_10_3748_wjg_v23_i36_6571
crossref_primary_10_1155_2019_2013674
crossref_primary_10_5500_wjt_v11_i3_37
crossref_primary_10_1007_s40519_021_01287_1
crossref_primary_10_1016_j_jhep_2017_12_029
crossref_primary_10_1016_j_jhep_2021_04_044
crossref_primary_10_1016_j_actbio_2018_10_010
crossref_primary_10_33590_emjhepatol_10311541
crossref_primary_10_3748_wjg_v25_i33_4959
crossref_primary_10_1080_17474124_2019_1621164
crossref_primary_10_1136_gutjnl_2021_324243
crossref_primary_10_14218_JCTH_2021_00188
crossref_primary_10_1038_s41598_021_93294_6
crossref_primary_10_1371_journal_pone_0224506
crossref_primary_10_22516_25007440_1156
crossref_primary_10_1111_liv_13549
crossref_primary_10_3389_fped_2023_1194641
crossref_primary_10_1016_j_dld_2021_04_029
crossref_primary_10_1097_SGA_0000000000000461
crossref_primary_10_14218_JCTH_2018_00048
crossref_primary_10_1111_hepr_13442
crossref_primary_10_1186_s12876_019_0961_9
crossref_primary_10_1055_a_1010_6052
crossref_primary_10_3138_canlivj_2020_0040
crossref_primary_10_3350_cmh_2019_0001n
crossref_primary_10_1002_hep4_1435
crossref_primary_10_1007_s11695_019_04192_w
crossref_primary_10_1159_000526503
crossref_primary_10_33590_emj_10314271
crossref_primary_10_1016_j_cgh_2020_06_045
crossref_primary_10_1097_MEG_0000000000002412
crossref_primary_10_1080_17474124_2018_1415756
crossref_primary_10_1016_j_cld_2017_08_004
crossref_primary_10_1155_2018_8490242
crossref_primary_10_1016_j_banm_2023_03_014
crossref_primary_10_1111_1751_2980_12685
crossref_primary_10_1007_s11901_017_0368_4
crossref_primary_10_1016_j_metop_2021_100158
crossref_primary_10_1088_1361_6560_abd593
crossref_primary_10_1016_j_jhep_2021_05_025
crossref_primary_10_18525_cu_2024_9_2_70
crossref_primary_10_1111_hepr_13831
crossref_primary_10_1111_liv_14325
crossref_primary_10_1007_s10620_020_06269_4
crossref_primary_10_1111_liv_14167
crossref_primary_10_1155_2021_6662760
crossref_primary_10_1016_j_cgh_2018_04_062
crossref_primary_10_1002_hep4_1467
crossref_primary_10_1016_j_clinre_2023_102183
crossref_primary_10_1111_1751_2980_12830
crossref_primary_10_1080_17512433_2017_1299573
crossref_primary_10_1055_a_2015_5693
crossref_primary_10_1002_hep_30672
crossref_primary_10_1016_j_jhepr_2020_100067
crossref_primary_10_1053_j_gastro_2019_01_042
crossref_primary_10_1007_s12072_017_9795_0
crossref_primary_10_1097_HEP_0000000000000843
crossref_primary_10_1002_hep_29067
crossref_primary_10_1371_journal_pone_0200656
crossref_primary_10_1016_j_aohep_2020_01_003
crossref_primary_10_1002_hep_29065
crossref_primary_10_1007_s10620_019_05702_7
crossref_primary_10_1016_j_ultrasmedbio_2022_03_019
crossref_primary_10_1111_hepr_13821
crossref_primary_10_14366_usg_19034
crossref_primary_10_1016_j_cgh_2017_09_044
crossref_primary_10_3390_cancers12102778
crossref_primary_10_1016_j_jhep_2017_05_011
crossref_primary_10_1136_gutjnl_2018_317334
crossref_primary_10_1016_j_deman_2023_100161
crossref_primary_10_14366_usg_20147
crossref_primary_10_1111_jvh_12715
crossref_primary_10_1111_apt_14584
crossref_primary_10_1155_2019_2151302
crossref_primary_10_3390_jcm10081569
crossref_primary_10_1016_j_cgh_2017_12_018
crossref_primary_10_1159_000478944
Cites_doi 10.1016/j.jhep.2015.11.004
10.1016/j.cgh.2014.12.014
10.1053/j.gastro.2015.11.048
10.1002/hep.27368
10.1002/hep.27844
10.1111/j.1365-2036.2011.04668.x
10.1016/j.jhep.2015.10.016
10.1016/j.cgh.2012.09.025
10.1038/ajg.2012.331
10.1016/S0168-8278(03)00191-0
10.1053/j.gastro.2014.11.039
10.1097/MEG.0b013e3282f51992
10.1111/liv.12584
10.1111/jgh.13219
10.1002/hep.24694
10.1016/j.jhep.2013.08.011
10.1002/hep.23312
10.1002/hep.27362
10.1053/j.gastro.2015.04.043
10.1053/j.gastro.2005.03.084
10.2174/1381612811319290004
10.1111/liv.12809
10.1002/hep.24624
10.1016/j.jhep.2011.10.017
10.1097/MEG.0b013e32835f4c3d
10.1002/hep.25993
10.1002/hep.21496
ContentType Journal Article
Copyright 2016 by the American Association for the Study of Liver Diseases.
2017 by the American Association for the Study of Liver Diseases.
Copyright_xml – notice: 2016 by the American Association for the Study of Liver Diseases.
– notice: 2017 by the American Association for the Study of Liver Diseases.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
DOI 10.1002/hep.28843
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
AIDS and Cancer Research Abstracts
AIDS and Cancer Research Abstracts
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1527-3350
EndPage 1155
ExternalDocumentID 4321099633
27639088
10_1002_hep_28843
HEP28843
Genre article
Journal Article
Comparative Study
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OB
1OC
1ZS
1~5
24P
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AALRI
AANHP
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABLJU
ABMAC
ABOCM
ABPVW
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACLDA
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AECAP
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFGKR
AFPWT
AFUWQ
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RGB
RIG
RIWAO
RJQFR
ROL
RPZ
RWI
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
ABJNI
ACZKN
ADSXY
AEFGJ
AFNMH
AGQPQ
AGXDD
AHQVU
AIDQK
AIDYY
AIQQE
CITATION
MEWTI
WXSBR
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3863-ca711dcc793736f44f09e2f7b764a6e25dbb98adb3c7d64d07eb44215d3ee9fc3
IEDL.DBID DR2
ISSN 0270-9139
1527-3350
IngestDate Thu Sep 04 19:01:36 EDT 2025
Fri Sep 05 14:53:08 EDT 2025
Wed Aug 13 11:33:22 EDT 2025
Wed Feb 19 02:41:00 EST 2025
Wed Oct 01 04:13:19 EDT 2025
Thu Apr 24 23:09:10 EDT 2025
Wed Jan 22 16:15:13 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License 2016 by the American Association for the Study of Liver Diseases.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3863-ca711dcc793736f44f09e2f7b764a6e25dbb98adb3c7d64d07eb44215d3ee9fc3
Notes Potential conflict of interest: Dr. G. Wong, Dr. V. Wong, Dr. H. Chan received lecture fees from Echosens.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 27639088
PQID 1880177579
PQPubID 996352
PageCount 11
ParticipantIDs proquest_miscellaneous_1888956127
proquest_miscellaneous_1859733640
proquest_journals_1880177579
pubmed_primary_27639088
crossref_primary_10_1002_hep_28843
crossref_citationtrail_10_1002_hep_28843
wiley_primary_10_1002_hep_28843_HEP28843
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2017
2017-04-00
20170401
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: April 2017
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Hepatology (Baltimore, Md.)
PublicationTitleAlternate Hepatology
PublicationYear 2017
Publisher Wolters Kluwer Health, Inc
Publisher_xml – name: Wolters Kluwer Health, Inc
References 2015; 35
2015; 13
2013; 25
2015; 148
2015; 149
2000; 23
2005; 411
2016; 31
2011; 33
2003; 39
2012; 56
2014; 60
2012; 55
2012; 107
2013; 19
2013; 11
2015; 62
2013; 57
2015; 61
2015; 64
2015; 63
2005; 128
2016; 64
2008; 20
2007; 45
2010; 51
2016; 150
(hep28843-bib-0029-20241017) 2008; 20
(hep28843-bib-0011-20241017) 2015; 63
(hep28843-bib-0014-20241017) 2012; 55
(hep28843-bib-0012-20241017) 2015; 62
(hep28843-bib-0019-20241017) 2003; 39
(hep28843-bib-0028-20241017) 2015; 13
(hep28843-bib-0023-20241017) 2015; 35
(hep28843-bib-0015-20241017) 2011; 33
(hep28843-bib-0017-20241017) 2000; 23
(hep28843-bib-0004-20241017) 2015; 61
(hep28843-bib-0031-20241017) 2016; 64
(hep28843-bib-0009-20241017) 2012; 107
(hep28843-bib-0013-20241017) 2013; 11
(hep28843-bib-0006-20241017) 2005; 128
(hep28843-bib-0021-20241017) 2015; 35
(hep28843-bib-0008-20241017) 2016; 64
(hep28843-bib-0005-20241017) 2015; 149
(hep28843-bib-0007-20241017) 2013; 19
(hep28843-bib-0016-20241017) 2016; 31
(hep28843-bib-0020-20241017) 2005; 411
(hep28843-bib-0010-20241017) 2010; 51
(hep28843-bib-0001-20241017) 2015; 64
(hep28843-bib-0024-20241017) 2014; 60
(hep28843-bib-0025-20241017) 2016; 150
(hep28843-bib-0022-20241017) 2007; 45
(hep28843-bib-0003-20241017) 2015; 148
(hep28843-bib-0030-20241017) 2013; 25
(hep28843-bib-0018-20241017) 2013; 57
(hep28843-bib-0026-20241017) 2012; 55
(hep28843-bib-0002-20241017) 2014; 60
(hep28843-bib-0027-20241017) 2012; 56
28103627 - Hepatology. 2017 Jun;65(6):2128
28103641 - Hepatology. 2017 Jun;65(6):2126-2128
References_xml – volume: 11
  start-page: 295
  year: 2013
  end-page: 302
  article-title: Association between anthropometric parameters and measurements of liver stiffness by transient elastography
  publication-title: Clin Gastroenterol Hepatol
– volume: 56
  start-page: 833
  year: 2012
  end-page: 839
  article-title: Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan
  publication-title: J Hepatol
– volume: 411
  start-page: 313
  year: 2005
  end-page: 321
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 55
  start-page: 584
  year: 2012
  end-page: 593
  article-title: Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population‐based study from a developing country
  publication-title: Hepatology
– volume: 149
  start-page: 389
  year: 2015
  end-page: 397
  article-title: Liver fibrosis, but no other histologic features, associates with long‐term outcomes of patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 60
  start-page: 1920
  year: 2014
  end-page: 1928
  article-title: Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study
  publication-title: Hepatology
– volume: 148
  start-page: 547
  year: 2015
  end-page: 555
  article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States
  publication-title: Gastroenterology
– volume: 55
  start-page: 199
  year: 2012
  end-page: 208
  article-title: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients
  publication-title: Hepatology
– volume: 45
  start-page: 846
  year: 2007
  end-page: 854
  article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
  publication-title: Hepatology
– volume: 13
  start-page: 772
  year: 2015
  end-page: 9
  article-title: Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study
  publication-title: Clin Gastroenterol Hepatol
– volume: 150
  start-page: 626
  year: 2016
  end-page: 637
  article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography
  publication-title: Gastroenterology
– volume: 63
  start-page: 1817
  year: 2015
  end-page: 1827
  article-title: Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan and ARFI with liver biopsy
  publication-title: Hepatology
– volume: 23
  start-page: S4
  issue: Suppl.
  year: 2000
  end-page: S19
  article-title: Clinical practice recommendations 2000
  publication-title: Diabetes Care
– volume: 35
  start-page: 2392
  year: 2015
  end-page: 2400
  article-title: Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
  publication-title: Liver Int
– volume: 35
  start-page: 1566
  year: 2015
  end-page: 1573
  article-title: The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Liver Int
– volume: 19
  start-page: 5193
  year: 2013
  end-page: 5218
  article-title: Non invasive indexes for the assessment of patients with non‐alcoholic fatty liver disease
  publication-title: Curr Pharm Des
– volume: 107
  start-page: 1862
  year: 2012
  end-page: 1871
  article-title: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease
  publication-title: Am J Gastroenterol
– volume: 25
  start-page: 905
  year: 2013
  end-page: 911
  article-title: Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography
  publication-title: Eur J Gastroenterol Hepatol
– volume: 39
  start-page: 239
  year: 2003
  end-page: 244
  article-title: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease
  publication-title: J Hepatol
– volume: 60
  start-page: 110
  year: 2014
  end-page: 117
  article-title: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
  publication-title: J Hepatol
– volume: 33
  start-page: 1350
  year: 2011
  end-page: 1360
  article-title: Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index
  publication-title: Aliment Pharmacol Ther
– volume: 20
  start-page: 693
  year: 2008
  end-page: 701
  article-title: Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography
  publication-title: Eur J Gastroenterol Hepatol
– volume: 62
  start-page: 1101
  year: 2015
  end-page: 1110
  article-title: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 128
  start-page: 1898
  year: 2005
  end-page: 1906
  article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease
  publication-title: Gastroenterology
– volume: 64
  start-page: 73
  year: 2015
  end-page: 84
  article-title: Global epidemiology of non‐alcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence and outcomes
  publication-title: Hepatology
– volume: 51
  start-page: 454
  year: 2010
  end-page: 462
  article-title: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 57
  start-page: 1182
  year: 2013
  end-page: 1191
  article-title: Determination of reliability criteria for liver stiffness evaluation by transient elastography
  publication-title: Hepatology
– volume: 61
  start-page: 1547
  year: 2015
  end-page: 1554
  article-title: Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
  publication-title: Hepatology
– volume: 64
  start-page: 682
  year: 2016
  end-page: 690
  article-title: MERTK rs4374383 polymorphism affects the severity of fibrosis in non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 31
  start-page: 848
  year: 2016
  end-page: 855
  article-title: Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease
  publication-title: J Gastroenterol Hepatol
– volume: 64
  start-page: 1388
  year: 2016
  end-page: 1402
  article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease
  publication-title: J Hepatol
– volume: 64
  start-page: 1388
  year: 2016
  ident: hep28843-bib-0008-20241017
  article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.11.004
– volume: 411
  start-page: 313
  year: 2005
  ident: hep28843-bib-0020-20241017
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
– volume: 13
  start-page: 772
  year: 2015
  ident: hep28843-bib-0028-20241017
  article-title: Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2014.12.014
– volume: 64
  start-page: 73
  year: 2015
  ident: hep28843-bib-0001-20241017
  article-title: Global epidemiology of non‐alcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence and outcomes
  publication-title: Hepatology
– volume: 150
  start-page: 626
  year: 2016
  ident: hep28843-bib-0025-20241017
  article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.11.048
– volume: 61
  start-page: 1547
  year: 2015
  ident: hep28843-bib-0004-20241017
  article-title: Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
  publication-title: Hepatology
  doi: 10.1002/hep.27368
– volume: 62
  start-page: 1101
  year: 2015
  ident: hep28843-bib-0012-20241017
  article-title: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.27844
– volume: 33
  start-page: 1350
  year: 2011
  ident: hep28843-bib-0015-20241017
  article-title: Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2011.04668.x
– volume: 23
  start-page: S4
  issue: Suppl.
  year: 2000
  ident: hep28843-bib-0017-20241017
  article-title: Clinical practice recommendations 2000
  publication-title: Diabetes Care
– volume: 64
  start-page: 682
  year: 2016
  ident: hep28843-bib-0031-20241017
  article-title: MERTK rs4374383 polymorphism affects the severity of fibrosis in non‐alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.10.016
– volume: 11
  start-page: 295
  year: 2013
  ident: hep28843-bib-0013-20241017
  article-title: Association between anthropometric parameters and measurements of liver stiffness by transient elastography
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2012.09.025
– volume: 107
  start-page: 1862
  year: 2012
  ident: hep28843-bib-0009-20241017
  article-title: Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2012.331
– volume: 39
  start-page: 239
  year: 2003
  ident: hep28843-bib-0019-20241017
  article-title: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(03)00191-0
– volume: 148
  start-page: 547
  year: 2015
  ident: hep28843-bib-0003-20241017
  article-title: Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.11.039
– volume: 20
  start-page: 693
  year: 2008
  ident: hep28843-bib-0029-20241017
  article-title: Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0b013e3282f51992
– volume: 35
  start-page: 1566
  year: 2015
  ident: hep28843-bib-0023-20241017
  article-title: The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: Liver Int
  doi: 10.1111/liv.12584
– volume: 31
  start-page: 848
  year: 2016
  ident: hep28843-bib-0016-20241017
  article-title: Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.13219
– volume: 63
  start-page: 1817
  year: 2015
  ident: hep28843-bib-0011-20241017
  article-title: Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan and ARFI with liver biopsy
  publication-title: Hepatology
– volume: 55
  start-page: 584
  year: 2012
  ident: hep28843-bib-0014-20241017
  article-title: Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population‐based study from a developing country
  publication-title: Hepatology
  doi: 10.1002/hep.24694
– volume: 60
  start-page: 110
  year: 2014
  ident: hep28843-bib-0002-20241017
  article-title: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2013.08.011
– volume: 51
  start-page: 454
  year: 2010
  ident: hep28843-bib-0010-20241017
  article-title: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.23312
– volume: 60
  start-page: 1920
  year: 2014
  ident: hep28843-bib-0024-20241017
  article-title: Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study
  publication-title: Hepatology
  doi: 10.1002/hep.27362
– volume: 149
  start-page: 389
  year: 2015
  ident: hep28843-bib-0005-20241017
  article-title: Liver fibrosis, but no other histologic features, associates with long‐term outcomes of patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.04.043
– volume: 128
  start-page: 1898
  year: 2005
  ident: hep28843-bib-0006-20241017
  article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.03.084
– volume: 19
  start-page: 5193
  year: 2013
  ident: hep28843-bib-0007-20241017
  article-title: Non invasive indexes for the assessment of patients with non‐alcoholic fatty liver disease
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612811319290004
– volume: 35
  start-page: 2392
  year: 2015
  ident: hep28843-bib-0021-20241017
  article-title: Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
  publication-title: Liver Int
  doi: 10.1111/liv.12809
– volume: 55
  start-page: 199
  year: 2012
  ident: hep28843-bib-0026-20241017
  article-title: Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients
  publication-title: Hepatology
  doi: 10.1002/hep.24624
– volume: 56
  start-page: 833
  year: 2012
  ident: hep28843-bib-0027-20241017
  article-title: Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.10.017
– volume: 25
  start-page: 905
  year: 2013
  ident: hep28843-bib-0030-20241017
  article-title: Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0b013e32835f4c3d
– volume: 57
  start-page: 1182
  year: 2013
  ident: hep28843-bib-0018-20241017
  article-title: Determination of reliability criteria for liver stiffness evaluation by transient elastography
  publication-title: Hepatology
  doi: 10.1002/hep.25993
– volume: 45
  start-page: 846
  year: 2007
  ident: hep28843-bib-0022-20241017
  article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
  publication-title: Hepatology
  doi: 10.1002/hep.21496
– reference: 28103641 - Hepatology. 2017 Jun;65(6):2126-2128
– reference: 28103627 - Hepatology. 2017 Jun;65(6):2128
SSID ssj0009428
Score 2.5904388
Snippet Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). Controlled attenuation...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1145
SubjectTerms Adult
Age Factors
Aged
Analysis of Variance
Biopsy, Needle
Cohort Studies
Elasticity Imaging Techniques - methods
Elasticity Imaging Techniques - trends
Female
Hepatology
Humans
Immunohistochemistry
Liver Cirrhosis - pathology
Liver diseases
Male
Middle Aged
Multivariate Analysis
Non-alcoholic Fatty Liver Disease - pathology
Predictive Value of Tests
Quality Improvement
Risk Assessment
ROC Curve
Sensitivity and Specificity
Sex Factors
Title Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28843
https://www.ncbi.nlm.nih.gov/pubmed/27639088
https://www.proquest.com/docview/1880177579
https://www.proquest.com/docview/1859733640
https://www.proquest.com/docview/1888956127
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1527-3350
  dateEnd: 20241003
  omitProxy: true
  ssIdentifier: ssj0009428
  issn: 0270-9139
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0270-9139
  databaseCode: DR2
  dateStart: 19960101
  customDbUrl:
  isFulltext: true
  eissn: 1527-3350
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009428
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HPYgvfn-snhLFB1-61yZpkuKTyB2LcCLiwT0IJZ-43F53uXYF_c_878wkaZfzC_GtpJN2wmSSyczkNwi9cESUVlpRKCdpwYRvClVaW4TNWdVKKl4puOB88o4vTtnbs_psD70a78IkfIjJ4QaaEddrUHCl-8MdaOhnt5kTKRkgfVa0jiHaDzvoqIbFuqrh1FVCdLkZUYVKcjj1vLoX_WJgXrVX44ZzfBN9GllNeSbn8-2g5-bbTyiO_zmWW-hGNkTx6zRzbqM9191B105yqP0u-p7cDc7iDjy2XxTkuePNJRCAMPHa4xUkdWAffr3ulz3WX3NLWDa8hzUUX-xckHjZ4Yzi2mNw_8KHVarQuzTYq2EY--eoEVZTKQscbGuc0-pXgSdABe0SSjkG9PILyOrBgFzu-nvo9Pjo45tFkes8FIZKTgujRFVZYwCqj3LPmC8bR7zQgjPFHamt1o1UVlMjLGe2FE4zFmwVS51rvKH30X7g2D1E2HEXDkw0tEFf6WXJrWcNtaSUoQ-doZejxFuTQdChFseqTfDNpA2iaKMoZuj5RLpJyB-_IzoYp02blb9vAeKuEqIWzQw9m14HtYVYjOrcegs04SRHKWfl32ikhHvHRMzQgzQlJ05I2BcgRS0MKE6sP7PYLo7ex4dH_076GF0nYL7EDKUDtD9cbt2TYHwN-mnUsh8SGDEF
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o-lBQziwCVbr-21HYlLVVot0K0QaqVeUOT4IVZss6smiwT_jH9XT16r8hLiFjnjZKzx2OOZ8TcALz1T1GmnEuM1T4QKaWKoc0ncnM3YaCNHBi84T4_k5ES8Ox2fbsDr7i5Mgw_RO9xQM-r1GhUcHdI7a9TQz345ZFoLfgWuYnwO1fLNxzV4VCrqyqrx3EUxvpx2uEKU7fRdL-9Gv5iYly3Wess5uAWfOmabTJMvw1WVD-33n3Ac_3c0t-Fma4uS3Wby3IENX9yFa9M22n4PfjQeB-9IgU7brwZT3cnyHAlQnmQRyBzzOkiI_16Us5Lk39qWuHKEgMsoOVt7IcmsIC2Qa0nQA4wfNk2R3pklwVRV178NHBHTV7Mg0bwmbWb9PPKEwKBFA1ROEMD8DBN7CIKX-_I-nBzsH-9NkrbUQ2K5ljyxRo1GzlpE6-MyCBFo6llQuZLCSM_GLs9TbVzOrXJSOKp8LkQ0Vxz3Pg2WP4DNyLF_BMRLH89MPLZhXx00lS6IlDtGdezDB_CqE3lmWxx0LMcxzxoEZ5ZFUWS1KAbwoiddNuAfvyPa7uZN1up_mSHK3UipsUoH8Lx_HTUXwzGm8IsV0sTDHOdS0L_RaI1Xj5kawMNmTvacsLg1YJZaHFA9s_7MYjbZ_1A_PP530mdwfXI8PcwO3x6934IbDK2ZOmFpGzar85V_Em2xKn9aq9wF76o1IQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceFMWWjCIA5dsvbbXdsQJ0a6WR6sKUakHpMiJbbFim101WST4Z_139SROVuUlxC1yxslYM2OPx-NvAF44pqjVViXGaZ4I5dPEUGuTsDibsdFGjgxecD48ktMT8e50fLoBr7q7MC0-RB9wQ8to5ms08KX1e2vQ0C9uOWRaC34NrgsZdlfoEX1cY0eloimsGl5QPF5OO1ghyvb6rlcXo188zKsOa7PiTG7B547XNtHk63BV58Pix08wjv85mNtwM3qi5HWrOndgw5V3YeswnrXfg4s23uAsKTFk-81gojtZniMBSpMsPJljVgfx4deLalaR_HtsCfOG9ziJkrN1DJLMShJhXCuC8V_8sGlL9M4K4k1dd_3jsRExfS0LEpxrEvPq54EnhAUtW5hygvDlZ5jWQxC63FX34WRy8OnNNImFHpKCa8mTwqjRyBYFYvVx6YXwNHXMq1xJYaRjY5vnqTY254WyUliqXC5EcFYsdy71BX8Am4Fj9xCIky7smHhow77aayqtFym3jOrQhw_gZSfxrIgo6FiMY561-M0sC6LIGlEM4HlPumyhP35HtNOpTRatv8oQ426k1FilA3jWvw52i4cxpnSLFdKErRznUtC_0WiNF4-ZGsB2q5I9JywsDJijFgbUKNafWcymB8fNw6N_J30KW8f7k-zD26P3j-EGQ1emyVbagc36fOV2gyNW508ag7sEObYz0A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+noninvasive+prediction+of+liver+fibrosis+by+liver+stiffness+measurement+in+patients+with+nonalcoholic+fatty+liver+disease+accounting+for+controlled+attenuation+parameter+values&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Petta%2C+Salvatore&rft.au=Wong%2C+Vincent+Wai-Sun&rft.au=Camma%2C+Calogero&rft.au=Hiriart%2C+Jean-Baptiste&rft.date=2017-04-01&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=65&rft.issue=4&rft.spage=1145&rft.epage=1155&rft_id=info:doi/10.1002%2Fhep.28843&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon